ICON Public Limited (NASDAQ:ICLR) Receives $292.45 Average Price Target from Analysts

ICON Public Limited (NASDAQ:ICLR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen analysts that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $292.45.

Several analysts have recently issued reports on ICLR shares. Barclays reduced their price objective on ICON Public from $330.00 to $275.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. Leerink Partners reaffirmed an "outperform" rating and issued a $255.00 price target (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. The Goldman Sachs Group lowered their price objective on ICON Public from $370.00 to $280.00 and set a "buy" rating for the company in a research report on Friday, October 25th. Redburn Atlantic began coverage on shares of ICON Public in a report on Monday, October 14th. They issued a "neutral" rating and a $311.00 target price on the stock. Finally, Robert W. Baird decreased their price target on shares of ICON Public from $249.00 to $225.00 and set a "neutral" rating for the company in a research note on Wednesday, November 20th.

ICON Public Trading Up 3.8 %

NASDAQ:ICLR traded up $7.98 on Friday, reaching $217.47. 1,290,892 shares of the company's stock were exchanged, compared to its average volume of 1,551,858. The firm has a market capitalization of $17.94 billion, a price-to-earnings ratio of 24.24, a price-to-earnings-growth ratio of 1.59 and a beta of 1.21. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. The business has a fifty day moving average of $241.72 and a 200-day moving average of $290.47.

ICON Public (NASDAQ:ICLR - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business had revenue of $2.03 billion for the quarter, compared to analysts' expectations of $2.13 billion. During the same period in the previous year, the company earned $3.10 earnings per share. ICON Public's quarterly revenue was down 1.2% on a year-over-year basis. As a group, analysts expect that ICON Public will post 13.42 earnings per share for the current year.

Institutional Investors Weigh In On ICON Public

A number of institutional investors and hedge funds have recently bought and sold shares of ICLR. Foyston Gordon & Payne Inc acquired a new position in ICON Public during the third quarter worth approximately $11,672,000. Icon Wealth Advisors LLC grew its position in shares of ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company's stock worth $3,797,000 after acquiring an additional 11,840 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in shares of ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company's stock valued at $172,000 after acquiring an additional 151 shares during the period. Arkadios Wealth Advisors raised its position in ICON Public by 5.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company's stock valued at $371,000 after purchasing an additional 62 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company's stock valued at $147,000 after purchasing an additional 96 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.